Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La
Jolla), a leader in the development of innovative therapies intended to
significantly improve outcomes in patients suffering from
life-threatening diseases, today announced that George F.
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the
development of therapeutics to treat kidney disease, today announced
that Chief Executive Officer Pierre Legault will present a corporate
overview of the Company and meet with investors at the 17 th
Annual BIO CEO & Investor Conference in New York City.
NEWARK, CA--(Marketwired - February 04, 2015) - CymaBay Therapeutics Inc. (NASDAQ: CBAY) announced today that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the 17th Annual BIO CEO & Investor Conference on Monday, February 9 at 2:30 p.m. Eastern Time.
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company
focused on the discovery and development of G protein coupled receptor
(GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its
president and chief executive officer, will present a company overview
at the 17 th Annual BIO CEO & Investor Conference on Tuesday
February 10, 2015 at 8:00 a.m. EST in New York City.
Agenus Inc. (NASDAQ: AGEN), an immunology company developing a series of
immune-oncology checkpoint modulators (CPMs), heat shock protein
peptide-based vaccines, and immune adjuvants, today announced that the
Company will present at the 17 th Annual BIO CEO & Investor
Conference on Monday, February 9 th at 4:30 p.m. Eastern Time.
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Brad Smith,
Chief Financial Officer, will present a corporate overview at the 17th
Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:30
p.m. Eastern Time at the Waldorf Astoria in New York City.
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Chief Executive
Officer Rachel King will provide a company overview at the 17th
Annual BIO CEO & Investor Conference on Monday, February 9, 2015
at 3:00 p.m. Eastern Time.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.